Question

Describe how the body responds to transplants and how doctors are able to successfully perform transplants.

Answer 1

How the body responds to a transplanted organ or tissue
- Recognition of “nonself”: The immune system recognizes proteins on donor cells (especially the highly variable human leukocyte antigen — HLA — molecules) as foreign. That recognition triggers immune responses aimed at destroying or removing the foreign tissue.
- Main mechanisms of rejection:
- Hyperacute rejection: Minutes to hours after connection. Caused by preformed antibodies in the recipient (for example against blood-group antigens or donor HLA). Antibody binding activates complement and clotting, producing rapid thrombosis and loss of blood flow to the graft.
- Acute rejection: Days to months. Primarily T-cell–mediated: host T cells see donor antigens (directly on donor antigen-presenting cells or indirectly after host antigen-presenting cells process donor proteins) and attack graft cells. Antibody-mediated acute rejection can also occur when B cells produce antibodies that damage graft blood vessels.
- Chronic rejection: Months to years. A slow, progressive process driven by chronic immune injury and nonimmune factors (ischemia, hypertension, drug toxicity) that leads to fibrosis, scarring and narrowing of graft vessels (vasculopathy), gradually impairing function.
- Other important responses:
- Ischemia–reperfusion injury: damage during the transplant process that can amplify immune activation.
- In bone marrow (stem cell) transplants, the reverse problem can occur: graft-versus-host disease (GVHD), where donor immune cells attack recipient tissues.

How doctors make transplantation successful
- Careful donor–recipient selection and testing:
- ABO blood-group compatibility prevents immediate antibody-mediated rejection.
- HLA typing and crossmatching (mixing recipient serum with donor cells) identify and avoid preformed anti-donor antibodies.
- Donor screening for infections and other risk factors.
- Surgical and perioperative care:
- Skilled surgical techniques to minimize ischemic time and injury.
- Preservation solutions and hypothermia to protect organs before implantation.
- Close monitoring in the immediate post-op period to detect complications early.
- Immunosuppression to prevent rejection:
- Induction therapy (powerful short-term agents such as anti-thymocyte globulin or IL-2 receptor blockers) at the time of transplant to blunt the initial immune response.
- Maintenance therapy to prevent acute and chronic rejection, typically a combination of drugs with different mechanisms, for example:
- Calcineurin inhibitors (tacrolimus, cyclosporine) to inhibit T-cell activation.
- Antiproliferative agents (mycophenolate mofetil, azathioprine) to reduce lymphocyte division.
- Corticosteroids to broadly suppress inflammation and immunity.
- Newer agents: costimulation blockers (belatacept), monoclonal antibodies (rituximab for B cells), etc.
- Drug levels are monitored and doses adjusted to balance rejection risk versus infection/toxicity.
- Managing antibody-mediated barriers:
- Plasmapheresis, IVIG, rituximab and complement inhibitors can remove or reduce anti-donor antibodies to allow transplantation even when sensitization is present.
- Diagnosis and treatment of rejection:
- Surveillance (blood tests, imaging) and tissue biopsy to detect rejection early.
- Reversal strategies: increased immunosuppression (steroids, antibody therapies) for acute rejection; chronic rejection often requires supportive care and may ultimately need re-transplantation.
- Long-term care and monitoring:
- Lifelong immunosuppression increases infection and cancer risk, so recipients are monitored and given prophylaxis (antivirals, antibiotics) when appropriate.
- Management of cardiovascular risks, drug side effects and other comorbidities to prolong graft and patient survival.
- Special strategies and research:
- Desensitization protocols and ABO-incompatible transplants make more organs usable.
- Efforts to induce immune tolerance (mixed chimerism, regulatory T-cell therapies) aim to reduce or eliminate the need for lifelong immunosuppression.
- Advances in organ preservation, surgical technique, and matching have greatly improved success rates.

Bottom line
The immune system naturally attacks foreign tissue, and rejection can be rapid or slow. Successful transplantation depends on careful matching and testing, surgical technique, powerful and well-managed immunosuppression, close monitoring for rejection and complications, and ongoing improvements in immunology and transplant medicine that expand options and improve outcomes.